Jeffrey M Witkin

List of Publications by Year
in descending order

81 papers	3,306 citations	172207 29 h-index	161609 54 g-index
82 all docs	82 docs citations	82 times ranked	3366 citing authors

#	Article	IF	Citations
1	Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3182-3187.	3.3	217
2	A role for AMPA receptors in mood disorders. Biochemical Pharmacology, 2006, 71, 1273-1288.	2.0	211
3	Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders. Trends in Pharmacological Sciences, 1999, 20, 107-112.	4.0	192
4	The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence. , 2014, 141, 283-299.		166
5	Mood disorders: Regulation by metabotropic glutamate receptors. Biochemical Pharmacology, 2008, 75, 997-1006.	2.0	164
6	Metabotropic Glutamate 5 Receptor Antagonism Is Associated with Antidepressant-Like Effects in Mice. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 254-259.	1.3	161
7	Metabotropic Glutamate Receptors in the Control of Mood Disorders. CNS and Neurological Disorders - Drug Targets, 2007, 6, 87-100.	0.8	129
8	Decreases in nestlet shredding of mice by serotonin uptake inhibitors: Comparison with marble burying. Life Sciences, 2006, 78, 1933-1939.	2.0	112
9	Enhancement of antidepressant potency by a potentiator of AMPA receptors. Cellular and Molecular Neurobiology, 2003, 23, 419-430.	1.7	101
10	N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a Novel Metabotropic Glutamate 2 Potentiator with Potential Anxiolytic/Antidepressant Properties: In Vivo Profiling Suggests a Link between Behavioral and Central Nervous System Neurochemical Changes. Journal of Pharmacology and Experimental Therapeutics, 2011, 336, 165-177.	1.3	101
11	Acute and chronic effects of the synthetic neuroactive steroid, ganaxolone, against the convulsive and lethal effects of pentylenetetrazol in seizure-kindled mice: comparison with diazepam and valproate. Neuropharmacology, 2000, 39, 1184-1196.	2.0	84
12	A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies. Neuropsychopharmacology, 2016, 41, 1803-1812.	2.8	82
13	Preclinical Evaluation of Melanin-Concentrating Hormone Receptor 1 Antagonism for the Treatment of Obesity and Depression. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 429-438.	1.3	77
14	Forebrain-selective AMPA-receptor antagonism guided by TARP Î³-8 as an antiepileptic mechanism. Nature Medicine, 2016, 22, 1496-1501.	15.2	77
15	Sensitive and rapid behavioral differentiation ofN-methyl-d-aspartate receptor antagonists. Psychopharmacology, 1994, 114, 573-582.	1.5	75
16	Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets. Nature Reviews Drug Discovery, 2016, 15, 516-516.	21.5	58
17	Modulators of N-methyl-D-aspartate protect against diazepam- or phenobarbital-resistant cocaine convulsions. Life Sciences, 1991, 48, PL51-PL56.	2.0	57
18	Synthesis of (â˜)-11-O-Debenzoyltashironin: Neurotrophic Sesquiterpenes Cause Hyperexcitation. Journal of the American Chemical Society, 2017, 139, 9637-9644.	6.6	54

#	Article	IF	Citations
19	A Novel, Orally Bioavailable Nociceptin Receptor Antagonist, LY2940094, Reduces Ethanol Self-Administration and Ethanol Seeking in Animal Models. Alcoholism: Clinical and Experimental Research, 2016, 40, 945-954.	1.4	53
20	Discovery of a Novel Series of Orally Active Nociceptin/Orphanin FQ (NOP) Receptor Antagonists Based on a Dihydrospiro(piperidine-4,7â€²-thieno[2,3-c]pyran) Scaffold. Journal of Medicinal Chemistry, 2014, 57, 3418-3429.	2.9	51
21	Rapid-acting antidepressants. Advances in Pharmacology, 2019, 86, 47-96.	1.2	49
22	Discovery of the First Î±-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antagonist Dependent upon Transmembrane AMPA Receptor Regulatory Protein (TARP) Î³-8. Journal of Medicinal Chemistry, 2016, 59, 4753-4768.	2.9	48
23	GABAkines â€“ Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors. , 2022, 234, 108035.		48
24	Constitutive deletion of the serotonin-7 (5-HT7) receptor decreases electrical and chemical seizure thresholds. Epilepsy Research, 2007, 75, 39-45.	0.8	44
25	Animal Models of Obsessiveâ€Compulsive Disorder. Current Protocols in Neuroscience, 2008, 45, Unit 9.30.	2.6	44
26	A Novel Nociceptin Receptor Antagonist LY2940094 Inhibits Excessive Feeding Behavior in Rodents: A Possible Mechanism for the Treatment of Binge Eating Disorder. Journal of Pharmacology and Experimental Therapeutics, 2016, 356, 493-502.	1.3	44
27	Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice. European Journal of Pharmacology, 2003, 474, 217-222.	1.7	43
28	Synthesis and Characterization of a Novel Î³-Aminobutyric Acid Type A (GABA_A) Receptor Ligand That Combines Outstanding Metabolic Stability, Pharmacokinetics, and Anxiolytic Efficacy. Journal of Medicinal Chemistry, 2016, 59, 10800-10806.	2.9	43
29	Hedonic and motivational responses to food reward are unchanged in rats with neuropathic pain. Pain, 2016, 157, 2731-2738.	2.0	38
30	Rapid-Acting Antidepressants. Current Pharmaceutical Design, 2018, 24, 2556-2563.	0.9	36
31	In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders. Psychopharmacology, 2006, 185, 240-247.	1.5	31
32	Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]h Acid Hydrochloride (LY3020371Â·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity. Journal of Medicinal Chemistry, 2016, 59, 10974-10993.	2.9	31
33	Preclinical findings predicting efficacy and sideâ€effect profile of <scp>LY</scp> 2940094, an antagonist of nociceptin receptors. Pharmacology Research and Perspectives, 2016, 4, e00275.	1.1	29
34	Analysis of behavioral effects of drugs. Drug Development Research, 1990, 20, 389-409.	1.4	28
35	The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders. Pharmacology Biochemistry and Behavior, 2022, 213, 173321.	1.3	27
36	Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in Mice. CNS and Neurological Disorders - Drug Targets, 2017, 16, 492-500.	0.8	25

#	Article	IF	Citations
37	Chronic pain impairs cognitive flexibility and engages novel learning strategies in rats. Pain, 2018, 159, 1403-1412.	2.0	24
38	mGlu2/3 receptor antagonism: A mechanism to induce rapid antidepressant effects without ketamine-associated side-effects. Pharmacology Biochemistry and Behavior, 2020, 190, 172854.	1.3	24
39	Dizocilpine-like discriminative stimulus effects of competitive NMDA receptor antagonists in mice. Psychopharmacology, 1997, 133, 43-50.	1.5	22
40	InÂvitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu 2/3 receptor antagonist. Neuropharmacology, 2017, 115, 100-114.	2.0	21
41	Negative allosteric modulation of alpha 5-containing GABAA receptors engenders antidepressant-like effects and selectively prevents age-associated hyperactivity in tau-depositing mice. Psychopharmacology, 2018, 235, 1151-1161.	1.5	21
42	Therapeutic Approaches for NOP Receptor Antagonists in Neurobehavioral Disorders: Clinical Studies in Major Depressive Disorder and Alcohol Use Disorder with BTRX-246040 (LY2940094). Handbook of Experimental Pharmacology, 2018, 254, 399-415.	0.9	20
43	Evaluation of 5-HT7 receptor antagonism for the treatment of anxiety, depression, and schizophrenia through the use of receptor-deficient mice. Behavioural Brain Research, 2019, 360, 270-278.	1.2	20
44	Effects of pentobarbital on punished behavior at different shock intensities. Pharmacology Biochemistry and Behavior, 1976, 5, 535-538.	1.3	19
45	The Positive Allosteric Modulator ofÎ±2/3-Containing GABA_AReceptors, KRM-II-81, Is Active in Pharmaco-Resistant Models of Epilepsy and Reduces Hyperexcitability after Traumatic Brain Injury. Journal of Pharmacology and Experimental Therapeutics, 2020, 372, 83-94.	1.3	18
46	mGlu5 receptor deletion does not confer seizure protection to mice. Life Sciences, 2008, 83, 377-380.	2.0	17
47	Pharmacological characterization of the neurotrophic sesquiterpene jiadifenolide reveals a non-convulsant signature and potential for progression in neurodegenerative disease studies. Biochemical Pharmacology, 2018, 155, 61-70.	2.0	17
48	A rapid punishment procedure for detection of anxiolytic compounds in mice. Psychopharmacology, 2004, 172, 52-57.	1.5	16
49	Auxiliary subunits of AMPA receptors: The discovery of a forebrain-selective antagonist, LY3130481/CERC-611. Biochemical Pharmacology, 2018, 147, 191-200.	2.0	15
50	Electroencephalographic, cognitive, and neurochemical effects of LY3130481 (CERC-611), a selective antagonist of TARP-Î³8-associated AMPA receptors. Neuropharmacology, 2017, 126, 257-270.	2.0	13
51	Central and peripheral muscarinic actions of physostigmine and oxotremorine on avoidance responding of squirrel monkeys. Psychopharmacology, 1989, 97, 376-382.	1.5	12
52	Behavioral effects of cocaine alone and in combination with selective dopamine antagonists in the squirrel monkey. Psychopharmacology, 1991, 103, 33-40.	1.5	12
53	Antiepileptogenic effects of the novel synthetic neuroactive steroid, ganaxolone, against pentylenetetrazol-induced kindled seizures: Comparison with diazepam and valproate. Drug Development Research, 1998, 44, 21-33.	1.4	12
54	Attenuation of the stimulant and convulsant effects of cocaine by 17-substituted-3-hydroxy and 3-alkoxy derivatives of dextromethorphan. Pharmacology Biochemistry and Behavior, 2003, 74, 313-323.	1.3	12

#	Article	IF	Citations
55	Behavioral Effects of a Novel Benzofuranyl-Piperazine Serotonin-2C Receptor Agonist Suggest a Potential Therapeutic Application in the Treatment of Obsessiveâ€“Compulsive Disorder. Frontiers in Psychiatry, 2017, 8, 89.	1.3	12
56	New Approaches to the Pharmacological Management of Major Depressive Disorder. Advances in Pharmacology, 2009, 57, 347-379.	1.2	11
57	Protein complexes as psychiatric and neurological drug targets. Biochemical Pharmacology, 2018, 151, 263-281.	2.0	11
58	Distinct cognitive and discriminative stimulus effects of ketamine enantiomers in rats. Pharmacology Biochemistry and Behavior, 2020, 197, 173011.	1.3	10
59	Imidazodiazepine Anticonvulsant, KRM-II-81, Produces Novel, Non-diazepam-like Antiseizure Effects. ACS Chemical Neuroscience, 2020, 11, 2624-2637.	1.7	10
60	mGlu5 receptor deletion reduces relapse to food-seeking and prevents the anti-relapse effects of mGlu5 receptor blockade in mice. Life Sciences, 2011, 89, 862-867.	2.0	9
61	Effects of 5-HT7 receptor antagonists on behaviors of mice that detect drugs used in the treatment of anxiety, depression, or schizophrenia. Behavioural Brain Research, 2019, 359, 467-473.	1.2	9
62	Animal models of fatigue in major depressive disorder. Physiology and Behavior, 2019, 199, 300-305.	1.0	9
63	Involvement of muscarinic receptor mechanisms in antidepressant drug action. Advances in Pharmacology, 2020, 89, 311-356.	1.2	9
64	Targeted Blockade of TARP-Î³8-Associated AMPA Receptors: Anticonvulsant Activity with the Selective Antagonist LY3130481 (CERC-611). CNS and Neurological Disorders - Drug Targets, 2018, 16, 1099-1110.	0.8	9
65	Rationalizing the binding and Î± subtype selectivity of synthesized imidazodiazepines and benzodiazepines at GABAA receptors by using molecular docking studies. Bioorganic and Medicinal Chemistry Letters, 2022, 62, 128637.	1.0	8
66	The value of human epileptic tissue in the characterization and development of novel antiepileptic drugs: The example of CERC-611 and KRM-II-81. Brain Research, 2019, 1722, 146356.	1.1	7
67	Commentary: Obstacles to the Discovery of Medicines for Psychiatric Disorders in Modern Times^{Â§}. CNS and Neurological Disorders - Drug Targets, 2015, 14, 4-6.	0.8	5
68	Design, synthesis and characterization of novel gammaâ€˜aminobutyric acid type A receptor ligands. Arkivoc, 2021, 2020, 242-256.	0.3	5
69	Behavioral effects of non-opioid antitussive anticonvulsants. Drug Development Research, 1989, 18, 57-65.	1.4	4
70	Some contextual and historical determinants of the effects of chlordiazepoxide on punished responding of rats. Psychopharmacology, 2002, 163, 488-494.	1.5	4
71	Commentary [The Mood in the Field of Antidepressant Drug Discovery]. CNS and Neurological Disorders - Drug Targets, 2011, 10, 762-763.	0.8	4
72	Consequences of constitutive deletion of melanin-concentrating hormone-1 receptors for feeding and foraging behaviors of mice. Behavioural Brain Research, 2017, 316, 271-278.	1.2	4

#	Article	IF	Citations
73	N-Substituted-3-alkoxy-derivatives of dextromethorphan are functional NMDA receptor antagonists in vivo: Evidence from an NMDA-induced seizure model in rats. Pharmacology Biochemistry and Behavior, 2021, 203, 173154.	1.3	4
74	Metabolism, pharmacokinetics, and anticonvulsant activity ofÂa deuterated analog of the Î±2/3â€selective GABAkine KRMâ€Hâ€81. Biopharmaceutics and Drug Disposition, 2022, 43, 66-75.	1.1	4
75	A medium throughput rodent model of relapse from addiction with behavioral and pharmacological specificity. Pharmacology Biochemistry and Behavior, 2019, 183, 72-79.	1.3	3
76	Can GABAkines quiet the noise? The GABAA receptor neurobiology and pharmacology of tinnitus. Biochemical Pharmacology, 2022, 201, 115067.	2.0	3
77	Rapid tolerance to behavioral effects of ethanol in rats: Prevention by R-(â^')-ketamine. Pharmacology Biochemistry and Behavior, 2021, 203, 173152.	1.3	2
78	The orally bioavailable imidazodiazepine, KRM-II-81, is a novel potentiator of Î±2/3-containing GABAA receptors with analgesic efficacy. , 2022, , 117-127.		2
79	Some behavioral effects of repeatedd-amphetamine administrations. Drug Development Research, 1990, 20, 31-41.	1.4	1
80	The romantic age of pharmacological science. Pharmacology Biochemistry and Behavior, 2022, 214, 173354.	1.3	1
81	Preface. Advances in Pharmacology, 2019, 86, xi-xiii.	1.2	0